Madopar Cr

Levodopa / Benserazide, the active ingredients in Madopar CR, are a combination of a dopamine precursor and a DOPA decarboxylase inhibitor presented as a controlled‑release oral tablet for oral use. They are employed to treat Parkinson's disease and related Parkinsonian syndromes by restoring central dopamine levels.

GNH USA supplies Madopar CR as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable logistics for global distribution, ensuring product integrity throughout the supply chain.

Madopar CR is indicated for the management of Parkinsonian disorders, addressing dopamine deficiency in the central nervous system.

- Parkinson's disease: improves motor function, reduces rigidity, bradykinesia and tremor, enhancing daily activities. - Parkinsonian syndrome: alleviates symptoms such as stiffness and slowed movement caused by secondary causes. - Secondary Parkinsonism: restores dopaminergic tone to mitigate drug‑induced or vascular Parkinsonian features.

Common and serious adverse reactions have been reported with levodopa/benserazide therapy.

Common Side Effects: - Nausea: gastrointestinal upset occurring early in treatment. - Vomiting: may accompany nausea or occur independently. - Dizziness: often related to orthostatic changes. - Orthostatic hypotension: drop in blood pressure upon standing. - Headache: mild to moderate intensity. - Insomnia: difficulty initiating or maintaining sleep.

Serious or Rare Side Effects: - Dyskinesia: involuntary, erratic movements affecting limbs or trunk. - Hallucinations: visual or auditory perceptual disturbances. - Severe hypotension: marked blood pressure fall requiring medical attention. - Neuroleptic malignant syndrome: rare life‑threatening reaction. - Cardiac arrhythmias: irregular heart rhythms observed in susceptible patients. - Anaphylaxis: acute allergic reaction with airway compromise.

When prescribing Madopar CR, clinicians should consider several safety precautions to minimize risks.

- Dose titration: start low and increase gradually to reduce gastrointestinal and cardiovascular side effects. - Renal impairment: adjust therapy and monitor renal function as excretion may be affected. - Cardiovascular disease: observe blood pressure and heart rate for orthostatic changes. - Psychiatric history: watch for emergence of hallucinations or psychosis. - Concomitant drugs: review all medications for potential interactions that may alter levodopa efficacy. - Store at ambient temperature below 25°C: keep in the original pack, protect from moisture.

Madopar CR can interact with other medicines, influencing its effectiveness or safety.

Major Interactions (Avoid): - Non‑selective MAO inhibitors: may cause hypertensive crisis when combined with levodopa. - Antipsychotics that block D2 receptors: reduce therapeutic benefit of levodopa. - Irreversible MAO‑B inhibitors: increase levodopa plasma levels and risk of toxicity.

Moderate Interactions (Monitor Closely): - Antihypertensive agents: additive effect on blood pressure leading to hypotension. - SSRIs or SNRIs: potential for serotonin syndrome when used with MAO inhibitors. - Diuretics: may enhance orthostatic hypotension and electrolyte disturbances.